Guerbet
| CAC Small | |
| ISIN | FR0000032526  |
| Founded | 1926 |
Guerbet (Euronext Paris: GBT ) is a France-based manufacturer of contrast agents used in medical imaging. The company was founded in 1926 by André Guerbet, the son of Marcel Guerbet who in 1901 discovered Lipiodol – the first iodinated X-ray contrast agent.[1]
In 2017 Guerbet’s revenues were €807.1 million. It employs over 2,700 people worldwide and has manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil. The company’s headquarters, formerly located in Villepinte, is currently located in Chicago, and its shares are included in the NASDAQ stock index.
In July 2015, Guerbet announced the takeover of a portion of Mallinckrodt's contrast media and application systems divisions. The acquisition was completed in November 2015.
In 2022, the United States Food and Drug Administration (FDA) approved Guerbet Group's Elucirem (Gadopiclenol), an MRI contrast agent. The product will be produced at Guerbet's factory in Raleigh, North Carolina[2] and at three of its French factories.[3]
An analysis of the growing global contrast media market, valued at $6.19 billion 2023 US dollars described Guerbet as a "key player."[4]
References
- ^ "Corporate history". Guerbet Group website. Archived from the original on 7 January 2019. Retrieved 8 January 2019.
- ^ "Guerbet Announces U.S. Food and Drug Administration (FDA) Approval of Elucirem™ (Gadopiclenol) Injection for Use in Contrast-Enhanced MRI". BioSpace. 2022-09-21. Retrieved 2025-07-20.
- ^ "US FDA Approves Guerbet's Elucirem MRI Contrast | Applied Radiology". Applied Radiology. September 21, 2022. Retrieved 2025-07-20.
- ^ Research and Markets. (June 11, 2024). Growing Prevalence of Chronic Diseases Propels Global Contrast Media Market to $9.5 Billion by 2029 - ResearchAndMarkets.com. Business Wire (English).
External links